Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

In Acute Myeloid Leukemia with Complex Karyotype TP53 Alterations Are Associated with Specific Genomic Aberrations and Predict Inferior Survival.

Frank G Rücker, M.D., Richard F Schlenk, M.D., Lars Bullinger, M.D., Helena Kett, Annegret Becker, Carla-Maria Kugler, Thorsten Zenz, MD, Peter Lichter, Ph.D., Jürgen Krauter, M.D., Brigitte Schlegelberger, M.D., Arnold Ganser, M.D., Hartmut Döhner, M.D., Konstanze Döhner, M.D.

Blood (2009) 114 (22): 2632.

https://doi.org/10.1182/blood.V114.22.2632.2632

Published: 2009

Journal Articles

Type and Number of Secondary Molecular Lesions Improve Outcome Prediction in Acute Myeloid Leukemia (AML) with inv(16) or t(16;16): A Study of the German-Austrian AML Study Group (AMLSG).

Peter Paschka, M.D., Juan Du, M.D., Richard F. Schlenk, M.D., Verena I. Gaidzik, M.D., Lars Bullinger, M.D., Andrea Corbacioglu, Ph.D., Manuela Zucknick, Ph.D., Axel Benner, M.Sc., Frank Stegelmann, M.D., Daniela Späth, Sabine Kayser, M.D., Brigitte Schlegelberger, M.D., Jürgen Krauter, M.D., Arnold Ganser, M.D., Hartmut Döhner, M.D., Konstanze Döhner, M.D.

Blood (2009) 114 (22): 824.

https://doi.org/10.1182/blood.V114.22.824.824

Published: 2009

Journal Articles

Mutations in the Fms-Related Tyrosine Kinase 3 (FLT3) Gene Independently Predict Poor Outcome in Acute Myeloid Leukemia (AML) with t(8;21): A Study of the German-Austrian AML Study Group (AMLSG).

Peter Paschka, M.D., Juan Du, M.D., Richard F. Schlenk, M.D., Lars Bullinger, M.D., Verena I. Gaidzik, M.D., Andrea Corbacioglu, Ph.D., Axel Benner, M.Sc., Manuela Zucknick, Ph.D., Frank Stegelmann, M.D., Daniela Späth, Sabine Kayser, M.D., Brigitte Schlegelberger, MD, Juergen Krauter, M.D., Arnold Ganser, M.D., Hartmut Döhner, Konstanze Döhner

Blood (2009) 114 (22): 825.

https://doi.org/10.1182/blood.V114.22.825.825

Published: 2009

Journal Articles

Analysis of the ETS Family Member Genes ERG, ETS2, ETS1 and FLI1 in Acute Myeloid Leukemia (AML) Patients with Normal Cytogenetics: Expression Levels and Impact On Clinical Outcome. A Study of the AMLSG.

Verena I. Gaidzik, M.D., Cailian Wang, M.D., Richard F. Schlenk, M.D., Lars Bullinger, M.D., Peter Paschka, M.D., Frank G. Rücker, M.D., Andrea Corbacioglu, Ph.D., Karina Eiwen, Jürgen Krauter, M.D., Brigitte Schlegelberger, MD, Arnold Ganser, M.D., Manuela Zucknick, Ph.D., Axel Benner, M.Sc., Hartmut Döhner, M.D., Konstanze Döhner, M.D.

Blood (2009) 114 (22): 1600.

https://doi.org/10.1182/blood.V114.22.1600.1600

Published: 2009

Journal Articles

Aberrant Expression of the Homeobox Gene CDX2 in Acute Myeloid Leukemia.

Claudia Scholl, MD, Dimple Bansal, Ph.D., Konstanze Dohner, M.D., Karina Eiwen, Benjamin H. Lee, M.D., Ph.D., Frank G. Rucker, M.D., Richard F. Schlenk, M.D., Lars Bullinger, M.D., Hartmut Dohner, M.D., D. Gary Gilliland, M.D., Ph.D., Stefan Frohling, M.D.

Blood (2006) 108 (11): 8.

https://doi.org/10.1182/blood.V108.11.8.8

Published: 2006

Journal Articles

Detection of RAS, KIT and FLT3 Gene Mutations in t(8;21)-Positive Acute Myeloid Leukemia (AML): Evaluation of the Clinical Relevance.

Juan Du, Richard F. Schlenk, M.D., Andrea Corbacioglu, Ph.D., Marianne Habdank, Claudia Scholl, M.D., Stefan Frohling, M.D., Lars Bullinger, M.D., Arnold Ganser, M.D., Hartmut Dohner, M.D., Konstanze Dohner, M.D.

Blood (2006) 108 (11): 2301.

https://doi.org/10.1182/blood.V108.11.2301.2301

Published: 2006

Journal Articles

RAS, KIT and FLT3 Gene Mutations in inv(16)/t(16;16)-Positive Acute Myeloid Leukemia (AML): Incidence and Relevance on Clinical Outcome.

Blood (2006) 108 (11): 2303.

https://doi.org/10.1182/blood.V108.11.2303.2303

Published: 2006

Journal Articles

Acute Myeloid Leukemia with Deletion 9q Is Associated with CEBPA Loss-of-Function Mutations.

Stefan Frohling, M.D., Richard F. Schlenk, M.D., Jurgen Krauter, M.D., Arnold Ganser, M.D., Christian Thiede, M.D., Gerhard Ehninger, M.D., Detlef Haase, M.D., Lana Harder, M.D., Claudia Scholl, M.D., Michael A. Caligiuri, M.D., Clara D. Bloomfield, M.D., Hartmut Dohner, M.D., Konstanze Dohner, M.D.

Blood (2004) 104 (11): 2896.

https://doi.org/10.1182/blood.V104.11.2896.2896

Published: 2004

NARROW

In Acute Myeloid Leukemia with Complex Karyotype TP53 Alterations Are Associated with Specific Genomic Aberrations and Predict Inferior Survival.

Type and Number of Secondary Molecular Lesions Improve Outcome Prediction in Acute Myeloid Leukemia (AML) with inv(16) or t(16;16): A Study of the German-Austrian AML Study Group (AMLSG).

Mutations in the Fms-Related Tyrosine Kinase 3 (FLT3) Gene Independently Predict Poor Outcome in Acute Myeloid Leukemia (AML) with t(8;21): A Study of the German-Austrian AML Study Group (AMLSG).

Analysis of the ETS Family Member Genes ERG, ETS2, ETS1 and FLI1 in Acute Myeloid Leukemia (AML) Patients with Normal Cytogenetics: Expression Levels and Impact On Clinical Outcome. A Study of the AMLSG.

Aberrant Expression of the Homeobox Gene CDX2 in Acute Myeloid Leukemia.

Detection of RAS, KIT and FLT3 Gene Mutations in t(8;21)-Positive Acute Myeloid Leukemia (AML): Evaluation of the Clinical Relevance.

RAS, KIT and FLT3 Gene Mutations in inv(16)/t(16;16)-Positive Acute Myeloid Leukemia (AML): Incidence and Relevance on Clinical Outcome.

Acute Myeloid Leukemia with Deletion 9q Is Associated with CEBPA Loss-of-Function Mutations.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only